Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells

被引:44
作者
Hayashi, T
Treon, SP
Hideshima, T
Tai, YT
Akiyama, M
Richardson, P
Chauhan, D
Grewal, IS
Anderson, KC
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
[3] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA
关键词
ADCC; CD40; multiple myeloma;
D O I
10.1046/j.1365-2141.2003.04322.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma (MM) is currently incurable, and novel therapies are needed. In this study, we examined a novel recombinant humanized monoclonal antibody against CD40 (rhuCD40 mAb) and demonstrate for the first time that rhuCD40 mAb induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD40-positive MM cells. Importantly, we show that rhuCD40 mAb induces autologous ADCC against primary patient MM cells, without triggering ADCC against normal B cells. This study, therefore, both demonstrates that rhuCD40 mAb triggers autologous ADCC against patient MM cells and provides the framework for the clinical evaluation of rhuCD40 mAb immunotherapy to improve patient outcome in MM.
引用
收藏
页码:592 / 596
页数:5
相关论文
共 12 条
[1]   Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].
Clynes, RA ;
Towers, TL ;
Presta, LG ;
Ravetch, JV .
NATURE MEDICINE, 2000, 6 (04) :443-446
[2]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[3]   CD40 ligand induces an antileukemia immune response in vivo [J].
Dilloo, D ;
Brown, M ;
Roskrow, M ;
Zhong, WY ;
Holladay, M ;
Holden, W ;
Brenner, M .
BLOOD, 1997, 90 (05) :1927-1933
[4]  
Francisco JA, 2000, CANCER RES, V60, P3225
[5]   INHIBITION OF HUMAN B-CELL LYMPHOMA GROWTH BY CD40 STIMULATION [J].
FUNAKOSHI, S ;
LONGO, DL ;
BECKWITH, M ;
CONLEY, DK ;
TSARFATY, G ;
TSARFATY, I ;
ARMITAGE, RJ ;
FANSLOW, WC ;
SPRIGGS, MK ;
MURPHY, WJ .
BLOOD, 1994, 83 (10) :2787-2794
[6]   Novel therapies for multiple myeloma [J].
Hayashi, T ;
Hideshima, T ;
Anderson, KC .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (01) :10-17
[7]  
Hayashi T, 2002, MOL CANCER THER, V1, P851
[8]   CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells [J].
Tai, YT ;
Podar, K ;
Gupta, D ;
Lin, B ;
Young, G ;
Akiyama, M ;
Anderson, KC .
BLOOD, 2002, 99 (04) :1419-1427
[9]  
TONG AW, 1994, BLOOD, V84, P3026
[10]   CD20-directed serotherapy in patients with multiple myeloma: Biologic considerations and therapeutic applications [J].
Treon, SP ;
Pilarski, TM ;
Belch, TR ;
Kelliher, A ;
Preffer, FI ;
Shima, Y ;
Mitsiades, CS ;
Mitsiades, NS ;
Szczepek, AJ ;
Ellman, L ;
Harmon, D ;
Grossbard, ML ;
Anderson, KC .
JOURNAL OF IMMUNOTHERAPY, 2002, 25 (01) :72-81